CPD Portal
7 key recommendations for management after PFO closure
The first position paper on the management of patients with patent foramen ovale (PFO) and left circulation embolism explores the available trial evidence and define the principles needed to guide decision-making.
As time goes by
The treatment of hypertension using drugs and the achieved benefits of such treatment is founded on a solid body of evidence representing a very large number of well-conducted randomised clinical trials.
Dapagliflozin DECLARE: Latest SGLT2 CV outcomes trial
MEDICAL CHRONICLE DECEMBER 2018 CPD 3 of 3: Recently the DECLARE trial was published evaluating in a randomised, double-blind, multinational, placebo- controlled trial, the effect of Dapagliflozin on safety and efficacy for macrovascular and microvascular outcomes.
Marijuana and the heart: what do we know?
We know little about cannabis consumption and the health effects of it, and more so its effects on cardiovascular disease.
The dos and don’ts of monitoring warfarin
MEDICAL CHRONICLE SEPTEMBER CPD 5 of 5: Since warfarin was given to American president Dwight Eisenhower following a myocardial infarction in 1955, it has been widely used as an oral anticoagulant.
Odyssey Outcome trial: cure for atherosclerosis?
The Odyssey Outcomes trial looked at reduction of LDL-cholesterol with a PCSK9-inhibitor.
BP control with current therapy
Initial combination treatment strategy may improve long-term BP control in a shorter time.
Enter Entresto: A new era in the treatment of heart failure
Globally the prevalence of heart failure is about one in 25 of the general population with increasing prevalence with increasing age.
New product launch: Dynaval
Pharma Dynamics announces the addition of Dynaval (valsartan) to its range of cardiovascular medicines.
Women’s hearts
Premature deaths caused by heart and blood vessel diseases (CVD) in people of working age (35-64 years) are expected to increase by 41% between 2000 and 2030.
Risk of sudden death in heart failure
Current recommended treatment for heart failure: Angiotensin-converting enzyme inhibitor (ACE-Inhibitors) or Angiotensin-receptor blockers (ARB), beta-blockers (Carvedilol, Bisoprolol and Metoprolol) and mineralocorticoid receptor antagonists.
Issues in hypertension
Hypertension increases the risk for coronary heart disease by two-fold and the risk for heart failure and stroke by four-fold.
What is the impact on CVD outcome of non-adherence?
As measured over the last two decades, the mortality from cardiovascular disease (CVD) has declined by about 50% and at least half of this decline has been attributed to the use of evidence-based medication.
Heart failure with preserved ejection fraction
Heart failure with reduced ejection fraction has shown improved outcomes with evidence-based treatment but heart failure with preserved ejection fraction has not shown any improved outcomes with treatment demonstrating our lack of effective therapies for this condition.
Stable angina pectoris
Ischaemic heart disease refers to a state in which there is inadequate blood supply (oxygen) to a portion of the myocardium due to an imbalance of myocardial oxygen supply and myocardial oxygen demand.
Manifestations of the metabolic syndrome: Part 1
This article deals with the definition, investigations, epidemiology and aetiology of metabolic syndrome.
Manifestations of the metabolic syndrome: part 2
Continuing on from Manifestations of the Metabolic Syndrome: Part 1, which appeared in the February issue of Medical Chronicle, which was all about diagnostic numbers, we look further at pathophysiology, progression, clinical presentations, prevention and practical management of the metabolic syndrome (Met-S).
